{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-347211","form_type":"8-K","ticker":"BSEM","cik":"0001658678","company_name":"BioStem Technologies, Inc.","filed_at":"2026-08-12T21:27:17+00:00","discovered_at":"2026-08-12T21:28:00.541177+00:00","generated_at":"2026-08-12T21:28:05.574315+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioStem Q2 revenue $7.9M (up 29% QoQ), net loss $9.0M, raises FY26 guide","bullets":["Q2 2026 net revenue $7.9M vs $6.1M Q1 2026 (+29%) and $11.0M Q2 2025; hospital $6.7M, physician $1.1M.","GAAP net loss $9.0M ($0.52/share) vs income $10,613 in Q2 2025; adjusted EBITDA loss $4.6M.","Cash $7.0M at June 30, 2026 (from $13.7M); used $5.5M in ops; closed $2.5M private placement.","Resolved $5.3M debt via $3.5M cash and $1.0M promissory note; uplisted to Nasdaq Capital Market Aug 7, 2026.","Raises FY2026 revenue guidance to $26-29M from $25-29M; issued eight new U.S. design patents."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-347211","json":"https://secwatch.observer/filing/0001193125-26-347211.json","markdown":"https://secwatch.observer/filing/0001193125-26-347211.md","text":"https://secwatch.observer/filing/0001193125-26-347211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658678/000119312526347211/0001193125-26-347211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658678/000119312526347211/bsem-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T21:28:05.574315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}